Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc demonstrates a positive outlook due to significant momentum following its inaugural R&D Day and the release of promising Phase 2a trial data, which indicated a notably improved therapeutic window for its lead asset, RAP-219. The results from the Phase 2 proof-of-concept study show that patients experienced meaningful reductions in long episodes and clinical seizures, coupled with enhancements in daily functioning, which supports the drug's potential in treating refractory focal onset epilepsy. Furthermore, the enthusiastic response from physicians and an improving reimbursement landscape for branded anti-seizure medications point to a favorable market environment that could enhance the commercial viability of RAP-219 in the treatment of central nervous system disorders.

Bears say

The financial analysis of Rapport Therapeutics Inc reveals a significant number of risks that contribute to a negative outlook on its stock. The potential overestimation of Phase 2a efficacy in its clinical trials could result in lower-than-expected outcomes in Phase 3 trials, exacerbated by the competitive landscape and challenges in obtaining favorable insurance coverage for its drugs. Furthermore, the necessity for additional funding to support clinical development and manufacturing raises concerns about the company's ability to achieve profitability and successfully navigate the drug approval process.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.